A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy
- Sponsor:
- Janssen Research and Development, LLC
- Sponsor Study ID:
- MajesTEC-7 (64007957MMY3005)
- CTO #:
- 104250
- NCT Number:
- NCT05552222
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Multiple Myeloma
- Study Objectives:
- To compare the efficacy of Tec-DR versus DRd and Tal-DR versus DRd.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Dominick, Anthony, at dominica@musc.edu .
- Study Coordinator, Bryan, Emma, at bryane@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina